- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Phase I trial of SGN-35 shows efficacy against refractory lymphomas
Results of a Phase 1 trial of Seattle Genetics' lead drug candidate brentuximab vedotin suggest that this hyped drug may warrant indications in patients with refractory lymphoma / relapsed lymphoma.
Read more about this news item at CancerTreatment.net.